New England Journal of Medicine· 2014Q1

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong et al.

6,869citations
Q1SCImago
2014year

Short summary

The angiotensin-neprilysin inhibitor LCZ696 significantly reduced the risk of cardiovascular death or heart failure hospitalization by 21.8% compared to enalapril (26.5%) in patients with heart failure and reduced ejection fraction.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Cardiology and Cardiovascular Medicine

Cardiology and Cardiovascular MedicineMedicine